Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.26%
)
US TECH 100
29,592.40
(
0.20%
)
Dow Jones
51,078.88
(
0.09%
)
Brent Oil
93.81
(
-2.25%
)
Bitcoin
70,303.02
(
-1.49%
)
News Focus
News Focus
Post# of 257683
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123050
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 119058

Thursday, 04/28/2011 9:49:22 PM

Thursday, April 28, 2011 9:49:22 PM

Post# of 257683

PFE—Didn't mention anything on how Humira arm was doing.

It would be nice to know how Tofacitinib did compared to Humira, but the comparison to placebo was technically the primary endpoint in ORAL Standard (http://clinicaltrials.gov/ct2/show/NCT00853385 ). I’m not sure we can infer anything about the Humira arm from the top-line data reported in today’s PR.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today